Literature DB >> 36100667

Comments to behavioral tests for antidepressant-like actions of (2R,6R)-hydroxynorketamine by Bonaventura et al.

Lijia Chang1, Kenji Hashimoto2.   

Abstract

Entities:  

Year:  2022        PMID： 36100667     DOI： 10.1038/s41380-022-01766-6

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN： 1359-4184            Impact factor:   13.437


× No keyword cloud information.
  13 in total

1.  What Are the Causes for Discrepancies of Antidepressant Actions of (2R,6R)-Hydroxynorketamine?

Authors:  Kenji Hashimoto; Yukihiko Shirayama
Journal:  Biol Psychiatry       Date:  2017-12-27       Impact factor: 13.382

2.  (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.

Authors:  Jun-Ichi Yamaguchi; Hidetoh Toki; Youge Qu; Chun Yang; Hiroyuki Koike; Kenji Hashimoto; Akiko Mizuno-Yasuhira; Shigeyuki Chaki
Journal:  Neuropsychopharmacology       Date:  2018-05-03       Impact factor: 7.853

Review 3.  Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.

Authors:  Kenji Hashimoto
Journal:  Biochem Pharmacol       Date:  2020-03-26       Impact factor: 5.858

4.  Depression researchers rethink popular mouse swim tests.

Authors:  Sara Reardon
Journal:  Nature       Date:  2019-07       Impact factor: 49.962

5.  Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.

Authors:  Jordi Bonaventura; Sherry Lam; Meghan Carlton; Matthew A Boehm; Juan L Gomez; Oscar Solís; Marta Sánchez-Soto; Patrick J Morris; Ida Fredriksson; Craig J Thomas; David R Sibley; Yavin Shaham; Carlos A Zarate; Michael Michaelides
Journal:  Mol Psychiatry       Date:  2021-04-15       Impact factor: 13.437

Review 6.  A systematic review of studies investigating the acute effects of N-methyl-D-aspartate receptor antagonists on behavioural despair in normal animals suggests poor predictive validity.

Authors:  Martin Viktorov; Matthew P Wilkinson; Victoria C E Elston; Medi Stone; Emma S J Robinson
Journal:  Brain Neurosci Adv       Date:  2022-03-12

7.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Polymnia Georgiou; Jonathan Fischell; Greg I Elmer; Manickavasagom Alkondon; Peixiong Yuan; Heather J Pribut; Nagendra S Singh; Katina S S Dossou; Yuhong Fang; Xi-Ping Huang; Cheryl L Mayo; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Nature       Date:  2016-05-04       Impact factor: 49.962

8.  Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.

Authors:  Yukihiko Shirayama; Kenji Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176

9.  Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.

Authors:  Allison C Nugent; Elizabeth D Ballard; Todd D Gould; Lawrence T Park; Ruin Moaddel; Nancy E Brutsche; Carlos A Zarate
Journal:  Mol Psychiatry       Date:  2018-02-27       Impact factor: 15.992

Review 10.  Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.

Authors:  Yan Wei; Lijia Chang; Kenji Hashimoto
Journal:  Mol Psychiatry       Date:  2021-05-07       Impact factor: 15.992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.